We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Healthcare, R&D IT Conference

By Biotechdaily staff writers
Posted on 28 Feb 2006
The accessibility and availability of managed healthcare information and data originating from claims clearinghouses, electronic transaction companies, and electronic medical records (EMR)/electronic healthcare records (EHR) vendors are creating new opportunities to optimize the drug development process. More...
The emerging role of these data sources in clinical research processes will be the focus of the upcoming Drug Information Association's (DIA; Horsham, PA, USA) Research and Development (R&D) Meets Healthcare Information Technology (HIT) conference, March 26-29, 2006, in Philadelphia (PA, USA).

R&D Meets Healthcare IT will provide clinical researchers with the latest information on using emerging databases for site and patient recruitment, obtaining reliable data from claims clearinghouses and EMR/HER vendors, and other pertinent topics from leaders in the private and public sectors as well as from the U.S Food and Drug Administration (FDA). In his keynote address, Dr. Scott Gottlieb, the FDA deputy commissioner for medical and scientific affairs, will discuss the potential of EMR/HER to transform healthcare ad public health initiatives.

This conference is co-sponsored by the Healthcare Information and Management Systems Society (HIMSS; Chicago, IL, USA), and will be held concurrently with DIA's 21st Annual Clinical Data Management Symposium and Exhibition, allowing participants to attend numerous lectures and discussions and examine an expanded exhibit space.

The Drug Information Association serves professionals in the biotechnology, pharmaceutical, and regulatory industries worldwide. Through its U.S. and international meetings, training courses, workshops, and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes.



Related Links:
Drug Information Association

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.